Introduction
============

The incidence of differentiated thyroid cancers (DTCs), including papillary thyroid cancer (PTC) and follicular thyroid cancer variants, is rising significantly globally over the past decades, with a wide geographic variation.[@b1-cia-11-1169] In Saudi Arabia, DTC is the second-most common malignancy, accounting for more than 10% of all cancers among middle-aged women.[@b2-cia-11-1169] Generally, age above 45 years is regarded as a poor prognostic marker in DTC, using the American Joint Cancer Committee/Union Internationale Contre le Cancer Tumor Nodes Metastasis staging system; the mortality rate climbs gradually starting at age 45 years and above.[@b3-cia-11-1169],[@b4-cia-11-1169] DTC in older patients (\>60 years) has some distinctive clinicopathological features: 1) large size of primary tumors at the time of diagnosis; 2) high risk of distant metastases at the time of presentation; 3) more aggressive histopathological variants of DTC; and 4) higher recurrence rates.[@b5-cia-11-1169],[@b6-cia-11-1169] The management of DTC in older patients remains controversial as there has been conflicting literature in regard to approach.[@b7-cia-11-1169] DTC in older patients is treated in a similar way as that in young adults, primarily because of scarcity of clinical and outcome data.[@b8-cia-11-1169]

In the present study, we aimed to evaluate the difference between different clinicopathological characteristics, and treatment outcomes of DTC in Saudi patients aged \<60 years and \>60 years.

Methods
=======

After a formal approval from the Institutional ethical committee of King Fahad Medical City and formal written consent from patients, medical records of 1,192 patients with confirmed DTC, who were managed in our institute during the period of 2000 and 2012, were retrieved using computer-based database system. As 45 years of age has been used as a cutoff in the staging of DTC in most of studies, the patients aged below 45 years were excluded.[@b9-cia-11-1169] Patients with incomplete information and those lost at follow-up were also excluded. Patients for analysis were retrieved in the following manner.

Grouping
--------

All patients were divided in two groups: 1) Group A: patients aged above 45 years but below 60 years, and 2) Group B: patients aged above 60 years.

Clinical variables
------------------

Descriptive data (age, sex, and symptoms, histology, size of primary tumor, variants, multifocality, lymphovascular invasion, staging, surgery types, neck dissection, adjuvant treatment and doses in millicurie \[mCi\], radiation therapy) were collected for each patient. Radiological data were collected from different imaging modalities (neck ultrasonography, whole body scan, computed tomography, fluoro-deoxyglucose positron emission tomography--computed tomography).

Statistical analysis
--------------------

The primary objective of this study was the disease-free survival (DFS) in elderly population, while secondary objectives were locoregional control (LRC), distant metastasis control (DMC), and overall survival (OS) rates.

Locoregional recurrence (LR) was defined as the gap between the surgery date and the date of radiologically detectable disease in the thyroid bed or in cervical lymph nodes on imaging in the presence of elevated thyroglobulin levels. Distant metastasis (DM) was defined as the gap between the surgery date and the date of documented disease outside the neck on imaging. DFS was described as the gap between the surgery date and the date of documented all-site relapse (LR and DM) or last follow-up (censored). OS was defined as the gap between the surgery date and the date of death or last follow-up (censored).

To determine the differences in various clinical variables, chi-square or Student's *t*-tests were used. *P*-value \<0.05 was considered statistically significant. All graphs were drawn with the Kaplan--Meier method, and the comparisons for various survival curves were performed with the log-rank test. All data analyses were done using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Clinical variables
------------------

Among the 1,192 registered DTC patients in our department, 252 adults (21.2%) aged below 60 years (Group A) and 118 (9.9%) aged above 60 years (Group B) were found to have DTC. The clinical, diagnostic, and therapeutic characteristics of both groups are described in [Table 1](#t1-cia-11-1169){ref-type="table"}. The mean age of study cohort at diagnosis was 57.2 years (range: 46--97). The study cohort (n=370) consisted of 292 (78.9%) females and 78 (21.1%) males. The predominant histopathology was PTC (93%). Classic variant PTC was more frequent in Group A (63.4%), whereas follicular variant PTC was more common 40.2% in Group B (*P*=0.002). The mean size of the primary tumor was 2.8 cm (range: 0.3--11), with no significant difference between Groups A and B (*P*=0.653). Pathologically involved cervical lymph nodes were seen more in elderly patients (51%, *P*=0.002). In Group B, distant metastases at the time of diagnosis were nearly three times more than that in Group A (*P*=0.010). Other features (extrathyroidal extension, multifocality, and lymphovascular space invasion) were significantly high in Group B (*P*=0.018, *P*=0.006, and *P*=0.003, respectively).

All patients were treated with total or near-total thyroidectomy. However, the frequency of neck dissection was seen more in Group A than in Group B (*P*=0.027). A total of 326 patients (88.1%) were treated with adjuvant radioactive iodine-131 (RAI) ablation with a median gap of 8.2 weeks (6.8--16.6 weeks) from the date of surgery.

Toxicity profile
----------------

Postsurgical complication rates including permanent hypocalcemia, postoperative bleeding, and wound infection were much higher in Group B as compared to Group A ([Table 2](#t2-cia-11-1169){ref-type="table"}). Similarly, acute and delayed (any grade) toxicities of adjuvant RAI were significantly higher in Group B than in Group A.

Outcomes
--------

The median follow-up period was 5.5 years (range: 0.7--10.4). For all patients, the estimated 10-year LRC and DMC rates were 91.8% and 89.6%, respectively. Group B was associated with inferior 10-year LRC and DMC rates (86.0% and 82.2%, respectively) than those in Group A (94.3% and 93.1%, respectively). A total of 25 LRs (6.8%) were observed: 12/252 in Group A and 13/118 in Group B (*P*=0.025) ([Table 3](#t3-cia-11-1169){ref-type="table"}). The LRs were managed by surgery (lateral neck exploration, 13 patients; completion thyroidectomy, five patients; excision, two patients), neck irradiation (three patients), and RAI ablation (16 patients). A total of 32 patients developed DM (8.7%): 14/252 in Group A and 18/118 in Group B (*P*=0.003). DMs were treated with RAI ablation (28 patients) and palliative radiotherapy (three patients). In addition, four patients were salvaged with targeted therapy. The projected 10-year DFS rates were 87.6% in Group A and 70.8% in Group B (*P*\<0.0001; [Figure 1](#f1-cia-11-1169){ref-type="fig"}). The estimated 10-year OS rates in both groups were found similar (*P*=0.491). Furthermore, in a multivariate analysis of Group B patients, positive lymph nodes (*P*\<0.0001) and partial response after first RAI ablation (*P*\<0.002) were found to be important independent prognostic factors predicting DFS.

Discussion
==========

Recent data have shown that the DFS rate in DTC declines gradually with each 5-year increment in age above 45 years.[@b3-cia-11-1169] However, the literature regarding clinicopathological features and treatment outcomes in elderly patients remains scarce and controversial, which is likely attributed to the definition of "elderly" itself.[@b5-cia-11-1169]--[@b8-cia-11-1169] Because of the lack of definition for "elderly", different studies have used different age limits for elderly patients; few of them have reported it around 80 years.[@b7-cia-11-1169],[@b10-cia-11-1169],[@b11-cia-11-1169] For the purpose of the present study, we defined "elderly" as patients aged above 60 years for threefold reasons; 1) according to the Saudi Arabia Population Census 2004, only 3.5% of population is above 65 years;[@b12-cia-11-1169] 2) thus by decreasing the age limit to 60 years, we achieved a large sample size; 3) which was also in agreement with other previously published data.[@b13-cia-11-1169]

In the present study, no significant difference was observed in primary tumor volumes between the two age groups, which is consistent with the reported literature.[@b14-cia-11-1169] In contrast to patients aged below 60 years, the pathological positive neck nodes were significantly higher in patients aged above 60 years, owing to the presence of lymphovascular space invasion, multifocality, and aggressive histopathological variants in elderly patients, which supports the routine use of lateral neck dissection in this age group.[@b15-cia-11-1169],[@b16-cia-11-1169]

In contrast to the study by Tartaglia et al,[@b17-cia-11-1169] patients aged above 60 years experienced significant postoperative hypoparathyroidism, hemorrhage, and wound infections. This observation favors the hypothesis of lobectomy/hemithyroidectomy for primary tumor in this age group, especially in patients with more than one associated comorbidity.[@b7-cia-11-1169],[@b9-cia-11-1169],[@b18-cia-11-1169],[@b19-cia-11-1169] Similarly, patients aged above 60 years experienced more RAI-induced acute and late (any grade) complications including a rare side effect of nasolacrimal duct obstruction, which we have previously reported.[@b20-cia-11-1169] A possible explanation could be the use of a fixed empiric dosing strategy (100--200 mCi) for RAI in our department. For the elderly age group, dosimetry-guided RAI therapy may be helpful. However, further studies are warranted.[@b21-cia-11-1169]

In contrast to previously published studies, our elderly patients experienced more all-site recurrences and had lower 10-year DFS rate (70.8%) even after extensive treatment that warrants more molecular-level studies.[@b4-cia-11-1169],[@b5-cia-11-1169]

Large sample size of study population and comparison of different clinicopathological characteristics and outcomes of elderly patients aged between 46 and 60 years were primary strengths of our study. However, the study might be criticized for 1) not evaluating thyroid-stimulating hormone (TSH) suppression therapy-related complications (including osteoporosis), as TSH suppression therapy can theoretically increase the risk of osteoporosis,[@b22-cia-11-1169] and 2) not having molecular-level data on elderly DTC.

Conclusion
==========

In conclusion, the frequency and clinicopathological features of DTC in Saudi elderly patients are similar to published data; however, some discrepancies (no difference in regard to tumor size between patients aged below 60 years and 60 years) were seen. Furthermore, elderly patients experienced more treatment-related complications when compared to patients aged \<60 years. Despite extensive treatment by thyroidectomy, neck dissection, RAI ablation, and TSH suppression therapy, a large proportion of elderly patients developed all-site recurrences. Large multi-institutional studies are warranted to suggest optimal treatment approaches for DTC in elderly patients. Furthermore, interdisciplinary tumor board meetings and competent follow-up of patients can minimize the disease- or treatment-related morbidities.
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###### 

Comparison of clinicopathological and treatment characteristics of patients with differentiated thyroid carcinoma aged below 60 years and above 60 years at presentation

  Variables                     Aged below 60 years (n=252)   Aged above 60 years (n=118)   *P*-value
  ----------------------------- ----------------------------- ----------------------------- -----------
  Age (years)                                                                               
   Median (range) SD            51.9 (46--60) ±4.2            68.6 (62--97) ±565.2          **0.022**
  Sex, n (%)                                                                                
   M                            50 (19.8)                     28 (12.3)                     
   F                            202 (74.1)                    90 (87.7)                     0.235
  Tumor size (cm)                                                                           
   Median (range) SD            2.92 (0.3--11) ±1.97          2.88 (0.2--10) ±1.87          0.653
  Histology, n (%)                                                                          
   Papillary                    235 (93.3)                    109 (92.4)                    0.063
   Classic                      149 (63.4)                    46 (42.2)                     **0.003**
   Follicular                   63 (26.8)                     44 (40.2)                     **0.002**
   Tall cell                    18 (7.6)                      13 (11.9)                     **0.041**
   Sclerosing                   5 (2.2)                       6 (5.5)                       **0.044**
   Follicular                   17 (6.7)                      9 (7.6)                       0.065
  T stage, n (%)                                                                            
   T~1~                         70 (27.8)                     28 (23.7)                     
   T~2~                         106 (42.1)                    36 (30.5)                     **0.018**
   T~3~                         62 (24.5)                     47 (39.9)                     
   T~4~                         14 (5.6)                      7 (5.9)                       
  N stage, n (%)                                                                            
   N~0~                         184 (73.1)                    67 (56.9)                     
   N~1~                         68 (26.9)                     51 (43.2)                     **0.002**
   N~1a~                        30 (44.2)                     30 (58.8)                     
   N~1b~                        38 (55.8)                     21 (41.2)                     
  M stage, n (%)                                                                            
   M~0~                         242 (96.0)                    105 (88.9)                    **0.010**
   M~1~                         10 (4.0)                      13 (11.0)                     
  Multifocality, n (%)                                                                      
   Yes                          76 (30.2)                     52 (44.1)                     **0.006**
   No                           176 (69.8)                    66 (55.9)                     
  LVSI, n (%)                                                                               
   Yes                          63 (25.0)                     48 (40.7)                     **0.003**
   No                           189 (75.0)                    70 (59.3)                     
  Surgery, n (%)                                                                            
   Total thyroidectomy          215 (85.3)                    99 (83.9)                     
   Near total thyroidectomy     37 (14.7)                     19 (16.1)                     0.065
  Neck dissection, n (%)                                                                    
   No                           46 (18.2)                     38 (32.2)                     
   Yes                          206 (81.7)                    80 (67.8)                     **0.027**
   Central                      104 (50.5)                    48 (60.0)                     
   Lateral                      102 (49.5)                    32 (40.0)                     
  Adjuvant RAI therapy, n (%)                                                               
   No                           35 (13.9)                     9 (6.9)                       
   Yes                          217 (84.9)                    109 (89.8)                    0.460
   30 mCi                       41 (18.9)                     15 (13.7)                     
   100 mCi                      48 (22.1)                     21 (19.3)                     
   150 mCi                      117 (53.9)                    58 (53.3)                     
   200 mCi                      11 (5.1)                      15 (13.7)                     

**Note:** Data in bold indicates statistical significance.

**Abbreviations:** n, number; DTC, differentiated thyroid cancer; SD, standard deviation; M, male; F, female; T, tumor; N, node; M, metastasis; LVSI, lymphovascular space invasion; RAI, radioactive iodine; mCi, millicurie.

###### 

Comparative analysis of complications of surgery and toxicities of radioactive iodine ablation in our cohort

  Toxicity                                 Aged below 60 years (n=252)   Aged above 60 years (n=118)   *P*-value
  ---------------------------------------- ----------------------------- ----------------------------- -----------
  Thyroidectomy, n (%)                                                                                 
   Hypoparathyroidism                      35 (15.2)                     28 (23.7)                     **0.042**
    Transient                              34 (97.2)                     26 (92.9)                     
    Permanent                              1 (2.8)                       2 (7.1)                       **0.043**
   Recurrent laryngeal nerve damage        3 (1.2)                       2 (1.7)                       0.071
   Postoperative hemorrhage                4 (1.6)                       8 (6.8)                       **0.011**
   Wound infection                         2 (0.8)                       3 (2.5)                       **0.021**
  RAI ablation, n (%)                                                                                  
   Acute                                   88 (34.9)                     42 (35.6)                     0.061
    Sialadenitis                           25 (28.4)                     15 (35.7)                     **0.042**
    Acute sickness (nausea and vomiting)   21 (23.8)                     10 (23.8)                     0.054
    Severe hair loss                       23 (26.2)                     8 (19.1)                      0.064
    Neck pain                              19 (21.6)                     9 (21.4)                      0.072
   RAI induced hyponatremia                0                             2 (1.7)                       **0.010**
  RAI ablation, n (%)                                                                                  
   Late                                    11 (4.3)                      9 (7.6)                       **0.034**
    Sicca syndrome                         3 (27.3)                      4 (44.4)                      
    Nasolacrimal duct obstruction          7 (63.6)                      4 (44.4)                      
    Second malignancy                      0                             0                             
    Infertility                            0                             0                             
    Lung fibrosis                          1 (9.1)                       1 (11.2)                      

**Note:** Data in bold indicates statistical significance.

**Abbreviations:** n, number; RAI, radioactive iodine.

###### 

Pattern of failure after thyroidectomy and radioactive iodine therapy in patients with differentiated thyroid cancer aged below 60 years and above 60 years

  Failures                        Aged below 60 years (n=252)   Aged above 60 years (n=118)   *P*-value
  ------------------------------- ----------------------------- ----------------------------- -----------
  Locoregional, n (%)             12 (4.8)                      13 (11.0)                     0.025
   Thyroid bed                    3 (25.0)                      4 (30.7)                      
   Lymph nodes                    9 (75.0)                      9 (69.3)                      
  Distant, n (%)                  14 (5.6)                      18 (115.3)                    0.003
   Lungs                          11 (78.6)                     13 (72.2)                     
   Bones                          3 (21.4)                      3 (16.7)                      
   Brain                          0                             2 (11.1)                      
  Locoregional + distant, n (%)   7 (2.8)                       11 (9.3)                      0.031
  10-year LRC rate                94.3%                         86.0%                         0.019
  10-year DMC rate                93.1%                         82.2%                         0.001
  10-year OS rate                 96.7%                         91.0%                         0.491

**Abbreviations:** n, number; LRC, locoregional control; DMC, distant metastasis control; OS, overall survival.
